Qualigen Therapeutics Presents Data on QN-302 at AACR’s Pancreatic Cancer Meeting
Posters include data regarding 1) mode of action, and
2) preclinical toxicology
Related news for (QLGN)
- Univest Securities, LLC Announces Closing of $41 Million Strategic Investment in Client Qualigen Therapeutics (NASDAQ: QLGN) from Client Faraday Future (NASDAQ: FFAI)
- 24/7 Market News Snapshot 30 September, 2025 – Qualigen Therapeutics, Inc. Common Stock (NASDAQ:QLGN)
- Qualigen Therapeutics Announces Successful Closing of $41 Million PIPE Financing Led by Faraday Future, Accelerating New Business Transformation into Crypto
- Faraday Future Announces Closing of Strategic $41 Million Investment in Qualigen Therapeutics (NASDAQ: QLGN) to Accelerate its Dual-Flywheel & Dual-Bridge Eco Strategy
- 24/7 Market News Snapshot 30 September, 2025 – Qualigen Therapeutics, Inc. Common Stock (NASDAQ:QLGN)